This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

SAVINGS DEADLINE EXPIRES:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Delivered as Hybrid Event from 16-18 November 2022
Live In-Person Conference Delivered 16-18 NovemberAustria Center Vienna

Dominik Altevogt, Ph.D
Associate Director Regulatory Affairs CMC at F.Hoffmann-La Roche Ltd

Profile

During over 10 years in the pharmaceutical industry, Dominik Altevogt has led multiple regulatory submissions and health authority interactions for small molecule drugs, with special focus on synthetic peptides and oligonucleotides. He started his career in the field of CMC regulatory affairs working for a peptide/oligonucleotide manufacturer. From 2014 to 2021, Dominik was working for F. Hoffmann-La Roche AG in Basel as a CMC Regulatory Manager. In 2021, he joined Novartis as Associate Director Regulatory Affairs CMC. Dominik holds a Ph.D. in organic chemistry from the University of Freiburg, Germany.

Agenda Sessions

  • Expediting the Development of Synthetic Therapeutic Oligonucleotides Through The Application of Platform Approaches

    09:15